Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23522762 | 0.82 | HTR2C (0.40) | HTR2CKDM1ARCOR1 | |
| SCHEMBL23522761 | 0.82 | HTR2C (0.40) | HTR2CKDM1ARCOR1 | |
| SCHEMBL24540920 | 0.82 | HTR2C (0.40) | HTR2CKDM1ARCOR1 | |
| SCHEMBL29650904 | 0.79 | CA1 (0.37) | HTR2CHTR2BHTR2A | |
| SCHEMBL24541211 | 0.79 | CA1 (0.37) | HTR2CHTR2BHTR2A | |
| SCHEMBL7294639 | 0.76 | SMN1; SMN2 (0.41) | HTR2BCHRM2 | |
| SCHEMBL8128459 | 0.76 | SMN1; SMN2 (0.41) | HTR2BCHRM2 | |
| SCHEMBL26084666 | 0.75 | HTR1A (0.51) | HTR2CHTR1AHTR2BHTR2AKDM1A | |
| SCHEMBL26084665 | 0.75 | HTR1A (0.51) | HTR2CHTR1AHTR2BHTR2AKDM1A | |
| SCHEMBL18159802 | 0.73 | HTR1A (0.46) | HTR2CHTR1AHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188828-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | US | disclosed |
| WO-2021124277-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188828-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | HTR2C 1863/4885HTR1A 1769/4885HTR2B 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.